Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Common Equity: 2020-2023

Historic Common Equity for Cullinan Therapeutics (CGEM) over the last 3 years, with Sep 2023 value amounting to $468.8 million.

  • Cullinan Therapeutics' Common Equity fell 20.01% to $468.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $468.8 million, marking a year-over-year decrease of 20.01%. This contributed to the annual value of $535.0 million for FY2022, which is 25.78% up from last year.
  • Cullinan Therapeutics' Common Equity amounted to $468.8 million in Q3 2023, which was down 6.16% from $499.6 million recorded in Q2 2023.
  • Cullinan Therapeutics' Common Equity's 5-year high stood at $604.6 million during Q2 2022, with a 5-year trough of $200.3 million in Q4 2020.
  • In the last 3 years, Cullinan Therapeutics' Common Equity had a median value of $469.7 million in 2021 and averaged $490.8 million.
  • In the last 5 years, Cullinan Therapeutics' Common Equity spiked by 112.35% in 2021 and then declined by 20.01% in 2023.
  • Over the past 4 years, Cullinan Therapeutics' Common Equity (Quarterly) stood at $200.3 million in 2020, then surged by 112.35% to $425.4 million in 2021, then rose by 25.78% to $535.0 million in 2022, then fell by 20.01% to $468.8 million in 2023.
  • Its Common Equity stands at $468.8 million for Q3 2023, versus $499.6 million for Q2 2023 and $485.6 million for Q1 2023.